For metastatic pancreatic cancer, treatment options expanded in late 2018 through 2019 with FDA approvals of larotrectinib (Vitrakvi) for the treatment of solid tumors with NTRK fusions; entrectinib (Rozlytrek), another pan-tumor agent for NTRK fusions; and olaparib (Lynparza), a PARP inhibitor that can be used as maintenance treatment for some patients with BRCA mutations.
The recently updated American Society of Clinical Oncology (ASCO) guidelines for the treatment of metastatic pancreatic cancer offer guidance on how to incorporate these therapies into clinical practice. Read more . . .